Articles related to BLEEDING/BLOOD DISORDERS

The phase 1 EXPLORER and phase 2 PATHFINDER trials demonstrated that avapritinib can produce complete and long-lasting clinical responses as well as molecular remission in KIT D816V patients. The complex mutational landscape of AdvSM, which is frequently associated with a hematologic neoplasm, poses significant management challenges.

A 75-y-o man is found to have an INR of 8.5 on routine monitoring. There is no evidence of bleeding, and he is otherwise well. He is instructed to stop warfarin. His hemoglobin comes back normal. What is the best next step in managing him: intervention or observation?

A quartet of current clinical trials involving first-in-class molecules and CRISPR gene editing show great promise. STELLAR investigates a fusion protein in PAH, CodeBreak 200 studies a first-in-class of KRAS inhibitor, EMERGENT-2 focuses on a new treatment for schizophrenia, and NCT04601051 studies a gene editing drug for one form of amyloidosis.

What is the best strategy for preventing stroke in patients with non-valvular AF: anticoagulants or left atrial appendage occlusion (LAAO)? The answer depends on the individual patient’s combination of stroke and bleeding risks. In this study, combined risks favored LAAO for higher bleeding risk, but that benefit became less certain at higher stroke risks.

Memorial Sloan Kettering oncologist Raajit Rampal presents a case report, discusses the rationale for the few treatment options available, and summarizes the 5-year follow-up data for the RESPONSE and RESPONSE 2 trials.

In this first part of a three-case series, a 65-year-old man received ruxolitinib for treatment and reported feeling much better after one month, and after two months of treatment, most of his symptoms had completely resolved and his blood cell counts were maintained under control.